DE68904922T2 - Piroxicam in waessrigen loesungen enthaltende arzneizubereitungen und verfahren zu deren herstellung. - Google Patents
Piroxicam in waessrigen loesungen enthaltende arzneizubereitungen und verfahren zu deren herstellung.Info
- Publication number
- DE68904922T2 DE68904922T2 DE8989105004T DE68904922T DE68904922T2 DE 68904922 T2 DE68904922 T2 DE 68904922T2 DE 8989105004 T DE8989105004 T DE 8989105004T DE 68904922 T DE68904922 T DE 68904922T DE 68904922 T2 DE68904922 T2 DE 68904922T2
- Authority
- DE
- Germany
- Prior art keywords
- piroxicam
- solution
- preparation
- process according
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 title claims abstract description 39
- 229960002702 piroxicam Drugs 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 238000000034 method Methods 0.000 title claims description 13
- 239000007864 aqueous solution Substances 0.000 title claims description 11
- 238000004519 manufacturing process Methods 0.000 title description 3
- 239000000203 mixture Substances 0.000 claims abstract description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 18
- 239000000243 solution Substances 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 10
- 239000004471 Glycine Substances 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 239000003513 alkali Substances 0.000 claims description 3
- 239000003381 stabilizer Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 229910001854 alkali hydroxide Inorganic materials 0.000 claims 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 claims 1
- 150000001447 alkali salts Chemical class 0.000 claims 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 claims 1
- 241000919811 Collyria Species 0.000 abstract description 2
- 230000002349 favourable effect Effects 0.000 abstract 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 9
- 230000036470 plasma concentration Effects 0.000 description 8
- 239000008215 water for injection Substances 0.000 description 7
- 102000004420 Creatine Kinase Human genes 0.000 description 6
- 108010042126 Creatine kinase Proteins 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 6
- 238000007918 intramuscular administration Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000007972 injectable composition Substances 0.000 description 4
- 229940096413 piroxicam 20 mg Drugs 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 235000019445 benzyl alcohol Nutrition 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- -1 alkaline earth metal salt Chemical class 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Cephalosporin Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT8820073A IT1216686B (it) | 1988-04-01 | 1988-04-01 | Formulazioni farmaceutiche acquose di piroxicam e procedimento per laloro preparazione. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE68904922D1 DE68904922D1 (de) | 1993-03-25 |
| DE68904922T2 true DE68904922T2 (de) | 1993-06-03 |
Family
ID=11163585
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE198989105004T Pending DE336200T1 (de) | 1988-04-01 | 1989-03-21 | Piroxicam in waessrigen loesungen enthaltende arzneizubereitungen und verfahren zu deren herstellung. |
| DE8989105004T Expired - Fee Related DE68904922T2 (de) | 1988-04-01 | 1989-03-21 | Piroxicam in waessrigen loesungen enthaltende arzneizubereitungen und verfahren zu deren herstellung. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE198989105004T Pending DE336200T1 (de) | 1988-04-01 | 1989-03-21 | Piroxicam in waessrigen loesungen enthaltende arzneizubereitungen und verfahren zu deren herstellung. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US4942167A (enExample) |
| EP (1) | EP0336200B1 (enExample) |
| JP (1) | JPH01299230A (enExample) |
| KR (1) | KR890015745A (enExample) |
| AT (1) | ATE85757T1 (enExample) |
| AU (1) | AU608142B2 (enExample) |
| CA (1) | CA1321352C (enExample) |
| DE (2) | DE336200T1 (enExample) |
| DK (1) | DK157689A (enExample) |
| ES (1) | ES2011232T3 (enExample) |
| FI (1) | FI90202C (enExample) |
| GR (2) | GR890300196T1 (enExample) |
| IE (1) | IE63714B1 (enExample) |
| IT (1) | IT1216686B (enExample) |
| MA (1) | MA21527A1 (enExample) |
| NO (1) | NO175406C (enExample) |
| NZ (1) | NZ228576A (enExample) |
| PT (1) | PT90124B (enExample) |
| ZA (1) | ZA892399B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1241088B (it) * | 1990-03-27 | 1993-12-29 | Chiesi Farma Spa | Procedimento per la preparazione di complessi piroxicam/ciclodestrina,prodotti ottenuti e loro composizioni farmaceutiche |
| HU205550B (en) * | 1990-11-27 | 1992-05-28 | Egyt Gyogyszervegyeszeti Gyar | Process for producing pyroxycam solution of increased stability, free from effects damaging tussues |
| US5362758A (en) * | 1992-09-18 | 1994-11-08 | Pfizer Inc. | Ophthalmic piroxicam solution |
| US5420124A (en) * | 1994-01-12 | 1995-05-30 | Kim; Young S. | Stable, painless piroxicam potassium injectable composition |
| CN1047077C (zh) * | 1994-01-15 | 1999-12-08 | 金元圭 | 稳定、无痛的吡罗昔康钾可注射组合物 |
| US5807568A (en) * | 1994-12-27 | 1998-09-15 | Mcneil-Ppc, Inc. | Enhanced delivery of topical compositions containing flurbiprofen |
| IT1283252B1 (it) * | 1996-03-15 | 1998-04-16 | Pulitzer Italiana | Soluzioni di piroxicam iniettabili per via parenterale |
| US6235724B1 (en) | 1996-07-03 | 2001-05-22 | Eisai Co., Ltd. | Injections containing lipid a analogues and process for the preparation thereof |
| DE10030345A1 (de) * | 2000-06-20 | 2002-01-10 | Boehringer Ingelheim Vetmed | Hochkonzentrierte stabile Meloxicamlösungen |
| US20020035107A1 (en) | 2000-06-20 | 2002-03-21 | Stefan Henke | Highly concentrated stable meloxicam solutions |
| DE10161077A1 (de) * | 2001-12-12 | 2003-06-18 | Boehringer Ingelheim Vetmed | Hochkonzentrierte stabile Meloxicamlösungen zur nadellosen Injektion |
| US8992980B2 (en) * | 2002-10-25 | 2015-03-31 | Boehringer Ingelheim Vetmedica Gmbh | Water-soluble meloxicam granules |
| JP4674162B2 (ja) | 2003-11-14 | 2011-04-20 | 千寿製薬株式会社 | アミノグリコシド系抗生物質およびブロムフェナクを含有する水溶液製剤 |
| EP1568369A1 (en) * | 2004-02-23 | 2005-08-31 | Boehringer Ingelheim Vetmedica Gmbh | Use of meloxicam for the treatment of respiratory diseases in pigs |
| DE102004021281A1 (de) * | 2004-04-29 | 2005-11-24 | Boehringer Ingelheim Vetmedica Gmbh | Verwendung von Meloxicam-Formulierungen in der Veterinärmedizin |
| DE102004030409A1 (de) * | 2004-06-23 | 2006-01-26 | Boehringer Ingelheim Vetmedica Gmbh | Neue Verwendung von Meloxicam in der Veterinärmedizin |
| EP1942902A1 (en) * | 2005-09-30 | 2008-07-16 | Boehringer Ingelheim Vetmedica Gmbh | Pharmaceutical preparation containing meloxicam |
| PL4378443T3 (pl) | 2009-10-12 | 2025-09-08 | Boehringer Ingelheim Vetmedica Gmbh | Pojemniki na kompozycje zawierające meloksykam |
| US20110218191A1 (en) * | 2010-03-03 | 2011-09-08 | Boehringer Ingelheim Vetmedica Gmbh | Use of meloxicam for the long term-treatment of kidney disorders in cats |
| CA2791805A1 (en) | 2010-03-03 | 2011-09-09 | Boehringer Ingelheim Vetmedica Gmbh | Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats |
| DE102010014290A1 (de) * | 2010-04-08 | 2011-10-13 | Hans Otto Meyer zu Spelbrink | Mittel zur prophylaktischen und therapeutischen Behandlung von Herpes-Infektionen |
| US9795568B2 (en) | 2010-05-05 | 2017-10-24 | Boehringer Ingelheim Vetmedica Gmbh | Low concentration meloxicam tablets |
| EP3932397A4 (en) * | 2019-03-01 | 2022-12-07 | Eurofarma Laboratórios S.A. | NON-STEROIDAL ANTI-INFLAMMATORY LYOPHILIZED PHARMACEUTICAL COMPOSITION |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE421792B (sv) * | 1976-01-12 | 1982-02-01 | Pfizer | Forfarande for framstellning av n-(2-pyridyl)-4-hydroxi-2-metyl-2h-1,2-benso-tiazin-3-karboxamid-1,1-dioxid |
-
1988
- 1988-04-01 IT IT8820073A patent/IT1216686B/it active Protection Beyond IP Right Term
-
1989
- 1989-03-21 AT AT89105004T patent/ATE85757T1/de not_active IP Right Cessation
- 1989-03-21 DE DE198989105004T patent/DE336200T1/de active Pending
- 1989-03-21 DE DE8989105004T patent/DE68904922T2/de not_active Expired - Fee Related
- 1989-03-21 ES ES89105004T patent/ES2011232T3/es not_active Expired - Lifetime
- 1989-03-21 EP EP89105004A patent/EP0336200B1/en not_active Expired - Lifetime
- 1989-03-28 PT PT90124A patent/PT90124B/pt not_active IP Right Cessation
- 1989-03-28 MA MA21773A patent/MA21527A1/fr unknown
- 1989-03-29 JP JP1077949A patent/JPH01299230A/ja active Pending
- 1989-03-31 IE IE103289A patent/IE63714B1/en not_active IP Right Cessation
- 1989-03-31 NO NO891367A patent/NO175406C/no unknown
- 1989-03-31 FI FI891570A patent/FI90202C/fi not_active IP Right Cessation
- 1989-03-31 US US07/331,457 patent/US4942167A/en not_active Expired - Fee Related
- 1989-03-31 DK DK157689A patent/DK157689A/da not_active IP Right Cessation
- 1989-03-31 NZ NZ228576A patent/NZ228576A/en unknown
- 1989-03-31 ZA ZA892399A patent/ZA892399B/xx unknown
- 1989-03-31 CA CA000595421A patent/CA1321352C/en not_active Expired - Fee Related
- 1989-03-31 KR KR1019890004209A patent/KR890015745A/ko not_active Abandoned
- 1989-03-31 AU AU32297/89A patent/AU608142B2/en not_active Ceased
-
1990
- 1990-11-29 GR GR89300196T patent/GR890300196T1/el unknown
-
1993
- 1993-02-18 GR GR930400298T patent/GR3007107T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK157689D0 (da) | 1989-03-31 |
| CA1321352C (en) | 1993-08-17 |
| FI90202C (fi) | 1994-01-10 |
| DE68904922D1 (de) | 1993-03-25 |
| IT1216686B (it) | 1990-03-08 |
| MA21527A1 (fr) | 1989-10-01 |
| ZA892399B (en) | 1989-11-29 |
| AU608142B2 (en) | 1991-03-21 |
| ES2011232A4 (es) | 1990-01-01 |
| EP0336200B1 (en) | 1993-02-17 |
| DE336200T1 (de) | 1990-03-01 |
| JPH01299230A (ja) | 1989-12-04 |
| DK157689A (da) | 1989-10-02 |
| GR890300196T1 (en) | 1990-11-29 |
| PT90124A (pt) | 1989-11-10 |
| NO891367L (no) | 1989-10-02 |
| IE891032L (en) | 1989-10-01 |
| PT90124B (pt) | 1994-06-30 |
| NZ228576A (en) | 1990-10-26 |
| FI90202B (fi) | 1993-09-30 |
| NO891367D0 (no) | 1989-03-31 |
| NO175406B (no) | 1994-07-04 |
| EP0336200A1 (en) | 1989-10-11 |
| FI891570L (fi) | 1989-10-02 |
| IE63714B1 (en) | 1995-05-31 |
| AU3229789A (en) | 1989-10-05 |
| ATE85757T1 (de) | 1993-03-15 |
| US4942167A (en) | 1990-07-17 |
| GR3007107T3 (enExample) | 1993-07-30 |
| ES2011232T3 (es) | 1994-01-16 |
| IT8820073A0 (it) | 1988-04-01 |
| FI891570A0 (fi) | 1989-03-31 |
| NO175406C (no) | 1994-10-12 |
| KR890015745A (ko) | 1989-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE68904922T2 (de) | Piroxicam in waessrigen loesungen enthaltende arzneizubereitungen und verfahren zu deren herstellung. | |
| DE60114249T2 (de) | Pharmazeutische zusammensetzung mit 2-(4-isobutylphenyl) propionsäure | |
| DE69920201T2 (de) | Zusammensetzungen enthaltend glykolderivate, alkohole und vitamin d | |
| DE69317444T2 (de) | Antivirale topische pharmazeutische zusammensetzungen | |
| DE69932939T2 (de) | Fulvinsäure und dessen verwendung zur behandlung von diversen krankheitszuständen | |
| DE69623354T2 (de) | Verwendung von hydrophoben zeolithen, sprize und methode zur entfernung von konservierungsmitteln aus einer polypeptidlösung | |
| EP0254902B1 (de) | Lösungen von Oxazaphosphorinen mit verbesserter Stabilität und Verfahren zu deren Herstellung | |
| DE69625200T2 (de) | Arzneimittel enthaltend lamotrigin | |
| DE602005002495T2 (de) | Injizierbare Formulierung mit Natriumdiclofenac, Beta-Cyclodextrin und einem Polysorbat | |
| DE3536560A1 (de) | Augentropfen enthaltend bromokryptin | |
| EP0277462B1 (de) | Verfahren zur Herstellung nasaler Lösungen enthaltend synthetisches Human calcitonin. | |
| DE10136404A1 (de) | Arzneiformulierung zur topischen Anwendung für die Therapie und Prophylaxe von Hyperhidrosis | |
| DE60101979T2 (de) | Lösung enthaltend N-[O-(p-pivaloyloxybenzenesulfonylamino)benzoyl]glyzin Mononatriumsalz Tetrahydrat und diese Lösung enthaltendes Arzneimittel | |
| DE69019404T2 (de) | Derivate von Penciclovir zur Behandlung von Hepatitis-B-Infektionen. | |
| DE69500490T2 (de) | Glattmuskelrelaxierende Arzneizubereitungen | |
| DE4404990C1 (de) | Verfahren zur Herstellung eines sterilen Prednisolongels | |
| DE3309076C2 (de) | Liposome und Verfahren zu ihrer Herstellung | |
| WO1998058639A1 (de) | Synergistisch wirkende zusammensetzungen zur selektiven bekämpfung von tumorgewebe | |
| DE2546474A1 (de) | Injizierbares pharmazeutisches thyroxinpraeparat und verfahren zu dessen herstellung | |
| DE69132145T2 (de) | Peritoneal wirksame medikamente | |
| DE3042975A1 (de) | Mikrodispersion mit einem wirkstoff und/oder einem reagens in salzform als disperser phase | |
| DE2515666B2 (de) | Piasminreiche Gammaglobulinfraktion, Verfahren zu deren Herstellung und das Verfahrensprodukt enthaltendes Gammaglobulinpräparat | |
| DE2518509C3 (de) | Pharmazeutisches Mittel für Antitumoraktivität, enthaltend Abrin | |
| DE2117762A1 (de) | Behandlung von Alopecia und pharmazeutische Präparation für die Durchführung der Behandlung | |
| DE2551962C3 (de) | Verwendung eines Extraktes aus verschiedenen Spezies von Helleborus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |